Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark Pharma gets...

    Glenmark Pharma gets USFDA approval to sell generic blood pressure medicine

    Written by Ruby Khatun Khatun Published On 2017-05-28T10:27:25+05:30  |  Updated On 28 May 2017 10:27 AM IST
    Glenmark Pharma gets USFDA approval to sell generic blood pressure medicine

    Glenmark Pharmaceuticals said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure.


    The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company said in a statement.

    These are the generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc.

    Glenmark's Olmesartan Medoxomil tablets will be manufactured by the company's manufacturing facility located in Goa, India, it added.

    Citing IMS Health sales data for the 12-month period ended March 2017, the company said Benicar achieved annual sales of about $950 million.

    Glenmark's current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA's (Abbreviated New Drug Application) pending approval with the USFDA.

    Shares of Glenmark Pharmaceuticals were trading 2.17 per cent up at Rs 625.20 on BSE.
    Abbreviated New Drug ApplicationapprovalBenicarblood pressureDaiichi SankyoFDAgenericGlenmarkGlenmark Pharmahigh blood pressureIMS Healthindian pharma newsOlmesartan medoxomilpharma newspharma news indiaUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok